Abstract:Objective: This study aimed to establish an antineoplastic drugs trigger tool based on Global Trigger Tool (GTT), to examine the performance by detecting adverse drug events (ADEs) in patients with cancer in a Chinese hospital (a retrospective review), and to investigate the factors associating with the occurrence of antineoplastic ADEs. Methods: Based on the triggers recommended by the GTT and those used in domestic and foreign studies and taking into account the scope of biochemical indexes in our hospital, some of them were adjusted. A total of 37 triggers were finally developed. Five hundred medical records of oncology patients discharged in our hospital from 1 June 2020 to 31 May 2021 were randomly selected according to the inclusion and exclusion criteria. These records were reviewed retrospectively by antineoplastic drugs trigger tool. The sensitivity and specificity of the triggers were analyzed, as well as the characteristics and risk factors for the occurrence of ADEs. Results: Thirty-three of the 37 triggers had positive trigger, and the sensitivity rate was 91.8% (459/500). For the specificity, the positive predictive value of overall ADEs was 46.0% (715/1556), the detection rate of ADEs was 63.0% (315/500), the rate of ADEs per 100 admissions was 136.0 (95% CI, 124.1–147.9), and the rate of ADEs per 1,000 patient days was 208.33 (95% CI, 201.2–215.5). The top three antineoplastic drugs related to ADEs were antimetabolic drugs (29.1%), plant sources and derivatives (27.1%), and metal platinum drugs (26.3%). The hematologic system was most frequently involved (507 cases, 74.6%), followed by gastrointestinal system (89 cases, 13.1%). Multivariate logistic regression analysis showed that the number of combined drugs (OR = 1.14; 95% CI, 1.07–1.22; P < 0.001) and the previous history of adverse drug reaction (ADR) (OR = 0.38; 95% CI, 0.23–0.60; P < 0.001) were the risk factors for ADEs. The length of hospital stay (OR = 0.40; 95% CI, 0.14–1.12; P < 0.05) and the previous history of ADR (OR = 2.18; 95% CI, 1.07–4.45; P < 0.05) were the risk factors for serious adverse drug events (SAE). Conclusion: The established trigger tool could be used to monitor antineoplastic drugs adverse events in patients with tumor effectively but still needs to be optimized. This study may provide some references for further research in order to improve the rationality and safety of antineoplastic medications.

Possible cause of drug extravasation in patients under tumor chemotherapy and application of a novel table to evaluate the risk of drug extravasation before chemotherapy

Drug Extravasation in a Large General Hospital in Hunan, China: A Retrospective Survey

Infusion chemotherapy infusion area emergency management and drug leakage contingency

Exploring Extravasation in Cancer Patients

Extravasation emergencies: state-of-the-art management and progress in clinical research

Risk Factors for Contrast Media Extravasation in Intravenous Contrast-Enhanced Computed Tomography: An Observational Cohort Study

Influence factors of chemotherapy toxicities in breast cancer patients

The incidence and risk factors of chemotherapy induced liver injury of the patients with gastrointestinal cancer adjuvant chemotherapy following radical surgery

Risk Factors Associated With Unplanned Acute Care in Outpatient Chemotherapy With Oral Anticancer Drugs as Monotherapy or Combination Therapy With Injectable Anticancer Drugs

Analysis of radiation dose to patients during abdominal interventional radiology

Validation of different personalized risk models of chemotherapy‐induced nausea and vomiting: results of a randomized, double‐blind, phase III trial of fosaprepitant for cancer patients treated with high‐dose cisplatin

Managing Chemotherapy Extravasation Across Transitions of Care: A Clinical Nurse Specialist Initiative

The application of Global Trigger Tool in monitoring antineoplastic adverse drug events: a retrospective study

Comparative study on the application of infusion route in patients with digestive tract tumor postoperative chemotherapy

Risk Factors Associated with Chemotherapy-Induced Nausea and Vomiting Among Women with Breast Cancer Receiving Highly Emetogenic Chemotherapy: Individual Patient-Based Analysis of Three Prospective Antiemetic Trials

Research on the Causes and Nursing Interventions of Extravasation During Intravenous Infusion

Incidence and Risk Assessment of Venous Thromboembolism in Cancer Patients Admitted to Intensive Care Unit for Postoperative Care.

A novel risk-scoring system conducing to chemotherapy decision for patients with pancreatic ductal adenocarcinoma after pancreatectomy

Assessments Blood Toxicity of Nurses Exposed to Anti-tumor Drugs before and after Establishment of PIVAS

Clinical analysis of 1946 cases of adverse drug reactions associated with chemotherapy in cancer patients